Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.70 |
| ▸ | PDE3B | Q13370 | 20/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 20/20 | 0.70 |
| ▸ | PDE5A | O76074 | 19/20 | 0.70 |
| ▸ | PDE1A | P54750 | 14/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 14/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 14/20 | 0.50 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155132 | 1.00 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7285109 | 0.97 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL2473235 | 0.91 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL15085278 | 0.90 | PDE5A (0.57) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7289581 | 0.86 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL15085332 | 0.86 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL12013957 | 0.83 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7287261 | 0.82 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7285598 | 0.79 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7279127 | 0.77 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | PDE4A 357/4885PDE4B 399/4885PDE4C 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.